2024-05-29 17:00:21 ET
Illumina, Inc. (ILMN)
Bernstein Strategic Decisions Conference
May 29, 2024 09:00 AM ET
Company Participants
Ankur Dhingra - Chief Financial Officer
Salli Schwartz - Vice President, Investor Relations
Conference Call Participants
Eve Burstein - Bernstein Research
Presentation
Eve Burstein
Thanks so much for joining us. My name is Eve Burstein. I cover US life science, tools and diagnostics here at Bernstein. And I'm delighted to be joined by our Illumina friends. So Ankur Dhingra, CFO, Salli Schwartz, Head of IR.
Ankur joined Illumina as CFO just a couple weeks ago. So we're glad to have you right out of the gate. He is formerly CFO at Summit Therapeutics and prior to that, CFO at CAREDx and spent a number of years at Agilent as well. Sally has been -- what 2.5 years.
Salli Schwartz
Almost.
Eve Burstein
Almost. All right happy almost 2.5 years anniversary.
Salli Schwartz
Thank you.
Salli Schwartz
As the VP of Investor Relations at Illumina. And before that, she was head of Investor Relations and Treasurer at MSCI. And she also spent a number of years with Moody's. So I'm excited. I have a lot of questions, but reminder to the audience, please feel free to submit questions via pigeonhole. I'll be looking at it as we're doing the conversation and I'll add them in.
Great with that, let's go ahead and get started. Ankur, do you want to kick us off? Anything you want to say right off the bat?
Ankur Dhingra
Yeah, let me just speak to a couple of things. We'll get into the details of the strategy, but here's two points that we've been talking about, mainly the priorities that I have as I'm walking into the company for -- this is now a month and a half now. And Jacob and I have talked about the top three priorities here in the near-term of getting back to growth as a company that remains priority number one....
Read the full article on Seeking Alpha
For further details see:
Illumina, Inc. (ILMN) Bernstein Strategic Decisions Conference (Transcript)